首頁 > 市場調查報告書 > 醫療設備

測量儀器生技設備

市場調查報告書

商品編碼

1629841

全球液相層析質譜市場 - 2024-2031

Global Liquid Chromatography Mass Spectrometry Market - 2024-2031

出版日期: 2024年12月30日 | 出版商:

DataM Intelligence | 英文 205 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年全球液相層析質譜市場規模達63.5億美元，預計2031年將達178.8億美元，2024-2031年預測期間複合年成長率為13.81%。

由於多個領域（尤其是醫療保健和製藥領域）研發 (R&D) 支出的增加，預計液相層析質譜 (LC-MS) 市場將大幅成長。對複雜分析方法的需求不斷成長，特別是在環境監測和個人化醫療領域，進一步增強了市場。

LC-MS 技術的持續發展，包括解析度、靈敏度和速度的提高，正在增強這些系統的整體性能和功能，促進其廣泛實施。技術進步，包括高解析度和混合質譜儀的出現，對於市場的成長至關重要。這些進步增強了分析能力，並促進更快、更精確的結果。

此外，自動化和資料處理軟體與 LC-MS 系統的整合顯著提高了工作流程效率和分析吞吐量。安捷倫科技公司的 Ultivo 三重四極桿 LC/MS 系統於 2022 年 1 月推出，展示了複雜的系統如何滿足許多應用對提高靈敏度和穩健性日益成長的需求，從而推動市場擴張。

此外，製藥和生技產業不斷增加的研發投資是 LC-MS 產業的重要催化劑。製藥公司在全球研發支出中佔有很大佔有率，特別是在生物製藥和個人化醫療方面，預計藥物發現、開發和臨床試驗中對質譜解決方案的需求將會增加。

動力學

製藥和生物技術的進步

隨著各行業對新藥發現和開發方法的需求不斷增加，LC-MS 系統的部署變得至關重要。 LC-MS 技術有助於對複雜生物基質中的多種物質進行準確識別和定量，顯著提高研究效率並促進創新發現。對 LC-MS 技術的日益依賴正在促進藥物開發的進步，從而有助於市場的成長。

製藥和生物技術產業研發 (R&D) 支出的大幅成長正在推動對質譜的需求。製藥公司在生物製藥、個人化醫療和其他先進治療領域的投資導致研發活動顯著增加。

這些業務佔全球研發支出的很大一部分，根據 2022 年歐盟工業研發投資記分牌，佔 21.5%，從而促進了從發現到臨床試驗的整個藥物開發過程中質譜分析的使用。因此，預計這種不斷增加的投資將在未來幾年推動 LC-MS 市場的持續成長。

食品和安全問題日益嚴重

人們對食品安全意識的不斷增強和嚴格的全球法規正在推動液相層析-質譜法 (LC-MS) 等現代分析方法的使用。該技術對於透過準確檢測和量化污染物和添加劑來確保遵守食品安全法規至關重要。

LC-MS 非常擅長檢測複雜的化學污染物混合物，為篩選、確認和定量提供無與倫比的靈敏度和選擇性。該技術解決食品真實性、營養評估和標籤精度等基本問題的能力使其成為先進食品檢測領域的基本要素。

食品標籤錯誤、微生物污染和食源性疾病的發生率越來越高，因此嚴格檢測程序的必要性越來越高。三重四極桿 (QqQ) 和飛行時間 (TOF) 技術等串聯質譜技術的進步改進了 LC-MS 系統的功能，使其對於遵守法規和增強消費者信心至關重要。

成本高

液相層析質譜 (LC-MS) 系統的高成本是產業擴張的一個相當大的障礙，特別是在財務限制限制使用複雜分析儀器的新興地區。設備的初始資本投資以及持續的維護和營運成本經常阻礙小型實驗室和研究組織實施 LC-MS 技術。這限制了這些技術的採用率，阻礙了整體市場的成長。

此外，與 LC-MS 相關的大量營運費用（包括消耗品、試劑和專業人員培訓）加劇了公司的財務壓力。因此，許多潛在客戶可能會選擇更經濟的選擇，例如傳統的色譜方法或質譜系統，其初始成本較低，但與 LC-MS 相比可能在精度和靈敏度方面存在缺陷。價格敏感度限制了 LC-MS 產業的成長潛力，特別是在學術界和小型公司等預算敏感的產業。

The Liquid Chromatography Mass Spectrometry (LC-MS) market is projected to undergo substantial growth due to heightened spending in research and development (R&D) across multiple sectors, especially in healthcare and pharmaceuticals. The increasing demand for sophisticated analytical methods, especially in environmental monitoring and personalized medicine, further strengthens the market.

The ongoing developments in LC-MS technology, including enhanced resolution, sensitivity and speed, are augmenting the overall performance and capabilities of these systems, facilitating their broad implementation. Technological advancements, including the emergence of high-resolution and hybrid mass spectrometers, are crucial to the market's growth. The advances enhance analytical capabilities and facilitate swifter and more precise outcomes.

Furthermore, the integration of automation and data processing software with LC-MS systems has markedly enhanced workflow efficiency and analytical throughput. The launch of Agilent Technologies' Ultivo Triple Quadrupole LC/MS system in January 2022 illustrates how sophisticated systems can satisfy the increasing demand for improved sensitivity and robustness across many applications, hence propelling market expansion.

Moreover, the increasing investments in research and development within the pharmaceutical and biotechnology industries are essential catalysts for the LC-MS industry. Pharmaceutical businesses represent a substantial share of global R&D spending, especially in biopharmaceuticals and personalized medicine, leading to an anticipated rise in the need for mass spectrometry solutions in drug discovery, development and clinical trials.

Dynamics

Advancements in Pharmaceutical and Biotechnology

The deployment of LC-MS systems is becoming essential, with the increasing demand for new drug discovery and development methods in various industries. LC-MS technology facilitates the accurate identification and quantification of diverse substances in intricate biological matrices, markedly enhancing research efficiency and fostering innovative discoveries. The increased dependence on LC-MS technologies is facilitating advancements in medication development, hence aiding market growth.

The significant rise in research and development (R&D) spending in the pharmaceutical and biotechnology industries is driving the demand for mass spectrometry. Investments by pharmaceutical corporations in biopharmaceuticals, personalized medicine and other advanced therapeutic domains have resulted in a notable increase in research and development activity.

These businesses represent a significant share of global R&D expenditure, including 21.5% as per the 2022 EU Industrial R&D Investment Scoreboard, thereby facilitating the use of mass spectrometry throughout the drug development process, from discovery to clinical trials. Thus, this increasing investment is anticipated to propel the ongoing growth of the LC-MS market in the forthcoming years.

Rising Food and Safety Concerns

The increasing awareness of food safety and stringent global regulations are propelling the utilization of modern analytical methods like Liquid Chromatography-Mass Spectrometry (LC-MS). This technology is essential for guaranteeing adherence to food safety regulations through accurate detection and quantification of pollutants and additives.

LC-MS is exceptionally proficient at detecting intricate mixtures of chemical pollutants, providing unmatched sensitivity and selectivity for screening, confirmation and quantification. The technology's capacity to tackle essential issues including food authenticity, nutritional evaluation and labeling precision has established it as a fundamental element in the advancing food testing domain.

The increasing occurrences of food mislabeling, microbial contamination and foodborne illnesses have heightened the necessity for rigorous testing procedures. Advancements in tandem mass spectrometry, such as triple quadrupole (QqQ) and time-of-flight (TOF) technologies, have improved the functionality of LC-MS systems, rendering them essential for regulatory adherence and consumer confidence.

High Cost

The high cost of Liquid Chromatography Mass Spectrometry (LC-MS) systems is a considerable obstacle to industry expansion, especially in emerging regions where financial limitations restrict access to sophisticated analytical instruments. The initial capital investment for the equipment, together with the continuous maintenance and operational costs, frequently dissuades smaller laboratories and research organizations from implementing LC-MS technology. This limits the adoption rate of these technologies, obstructing total market growth.

Moreover, the substantial operating expenses linked to LC-MS, encompassing consumables, reagents and specialist personnel training, exacerbate the financial strain on companies. Consequently, numerous prospective customers may choose more economical options, such as conventional chromatographic methods or mass spectrometric systems, which present reduced initial costs but may be deficient in precision and sensitivity compared to LC-MS. The price sensitivity constrains the growth potential of the LC-MS industry, particularly in budget-conscious sectors such as academics and small-scale companies.

Segment Analysis

The global liquid chromatography mass spectrometry market is segmented based on technology, application, end-user and region.

Revolutionizing Drug Development with LC-MS

LC-MS is essential for assessing medicines throughout different phases of the drug development lifecycle. From the preliminary phases of drug development, where it facilitates the separation and characterisation of prospective drug candidates from synthetic or natural substances, to sophisticated metabolism investigations (both in vitro and in vivo), LC-MS guarantees precise and dependable analytical outcomes.

Furthermore, LC-MS is crucial for detecting contaminants and degradation products, so guaranteeing the safety and efficacy of pharmaceutical formulations. Its capacity to identify and measure intricate molecular structures with exceptional sensitivity and specificity renders it an essential instrument for pharmaceutical research. The strong applicability of LC-MS systems in drug discovery and development enhances their demand, establishing them as essential tools in the pharmaceutical sector.

Geographical Penetration

Regulatory Support and Sustainable Urban Mobility in Europe

The North American Liquid Chromatography Mass Spectrometry (LCMS) market is witnessing significant growth, propelled by the swift advancement of the pharmaceutical sector and heightened spending in research and development (R&D). The region gains advantages from the involvement of prominent entities like Thermo Fisher Scientific, Agilent Technologies and Bio-Rad Laboratories, whose discoveries and commercial endeavors substantially contribute to promoting adoption. The demand for clinical diagnostic applications, along with heightened scientific understanding and the presence of competent professionals, further augments the use of LCMS systems.

Programs such as Clarivate Analytics' Life Science Alliances Program, which supports drug and medical device developers in enhancing research and development as well as commercialization, are anticipated to increase the need for LCMS systems. Moreover, the region's rising R&D investment highlights its potential for market expansion. US biopharmaceutical sector has allocated almost US$ 90 billion to R&D endeavors, underscoring the substantial prospects for LCMS applications in drug discovery, diagnostics and other advanced research domains.

Competitive Landscape

The major global players in the market include Danaher Corporation, PerkinElmer, Inc., Waters Corporation, Bruker Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Shimadzu Corporation, JEOL Ltd. and Newomics, Inc. and LECO Corporation.

Sustainability Analysis

The LC-MS (Liquid Chromatography-Mass Spectrometry) market is progressively conforming to the tenets of green chemistry, emphasizing the reduction of environmental effect while improving laboratory efficiency. Green chemistry promotes the utilization of eco-friendly reaction medium, the reduction of hazardous chemical waste and the optimization of laboratory procedures to decrease energy usage. Liquid chromatography, a prevalent analytical technique in pharmaceuticals, biotechnology and environmental monitoring, has considerable opportunities for the incorporation of sustainable practices.

The implementation of environmentally friendly technologies is essential for promoting sustainability in the LC-MS sector. Contemporary chromatography apparatus has improved in energy efficiency and the adoption of methods like solvent recycling and waste reutilization further promotes sustainability. Furthermore, the utilization of supercritical CO2 and alternative green solvents offers a promising strategy for minimizing the environmental impact of the approach.

Suppliers such as Scientific Laboratory Supplies (SLS) and Merck are facilitating the transition by offering environmentally sustainable solutions that promote green chemistry in laboratories. As the industry increasingly prioritizes sustainability, these initiatives are crucial for transforming LC-MS into both a potent analytical instrument and a more environmentally responsible option.

Technological Advancement

The LC-MS market is experiencing substantial technological developments, propelled by innovations in low-flow LC-MS applications and the integration of cutting-edge technology. The shift of nano-, capillary- and micro-flow LC-MS from research and development laboratories to widespread industrial use has transformed analytical processes, especially in proteomics and drug discovery.

Innovations such as ion mobility spectrometry (IMS) augment molecular characterisation by providing an extra dimension of separation, hence enhancing specificity and analytical peak capacity for intricate materials. The developments, along with efforts to enhance time-of-flight detection, are establishing new benchmarks for precision and resolution in biomolecular analysis.

Manufacturers are prioritizing sustainability by adopting environmentally friendly methods that line with global development objectives. Advanced systems, such as SCIEX's QTOF instruments, enhance speed and sensitivity while integrating novel capabilities like SWATH collection and EAD fragmentation for thorough compound analysis.

Innovative integrations, such as icIEF-UV/MS and CE-ESI, significantly improve sensitivity and quantification for biotherapeutic applications while minimizing ion suppression. These technical advancements are transforming the capabilities of LC-MS systems, ensuring they fulfill the evolving requirements of the pharmaceutical and biopharmaceutical sectors with accuracy, efficiency and environmental awareness.

By Technology

Time of Flight
Quadrupole - Time of Flight
Hybrid LC-MS
Ion Trap LC-MS
Others

By Application

Drug Discovery and Development
Clinical Diagnostics
Environmental Testing
Forensic Testing
Pharmaceutical and Biotechnology
Others

By End-User

Academic Research Institutions
Contract Research Organizations
Biopharmaceutical Companies
Hospitals and Diagnostic Centers
Pathology Laboratories
Forensic Laboratories
Others

By Region

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Key Developments

In June 2024, Thermo Fisher Scientific Inc. introduced the Thermo Scientific Stellar Mass Spectrometer (MS), a novel solution aimed at advancing translational omics research. This sophisticated instrument provides rapid throughput, elevated sensitivity and intuitive operation, facilitating researchers in achieving revolutionary findings with greater efficiency.
In April 2024, Waters Corporation launched the Alliance iS Bio HPLC System, aimed at addressing the operational and analytical issues encountered by biopharma quality control laboratories. This cutting-edge HPLC system combines sophisticated bio-separation technology with integrated instrument intelligence capabilities, designed to improve efficiency for biopharma quality control analysts. This approach enables users to potentially decrease common errors by up to 40%, therefore reducing the time allocated to addressing issues associated with failed runs and out-of-specification outcomes.

Why Purchase the Report?

To visualize the global liquid chromatography mass spectrometry market segmentation based on technology, application, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the liquid chromatography mass spectrometry market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global liquid chromatography mass spectrometry market report would provide approximately 62 tables, 61 figures and 205 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Advancements in Pharmaceutical and Biotechnology
  - 4.1.1.2. Rising Food and Safety Concerns
- 4.1.2. Restraints
  - 4.1.2.1. High Cost
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. By Technology

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 6.1.2. Market Attractiveness Index, By Technology
6.2. Time of Flight*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Quadrupole - Time of Flight
6.4. Hybrid LC-MS
6.5. Ion Trap LC-MS
6.6. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Drug Discovery and Development*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Clinical Diagnostics
7.4. Environmental Testing
7.5. Forensic Testing
7.6. Pharmaceutical and Biotechnology
7.7. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Academic Research Institutions*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Contract Research Organizations
8.4. Biopharmaceutical Companies
8.5. Hospitals and Diagnostic Centers
8.6. Pathology Laboratories
8.7. Forensic Laboratories
8.8. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. US
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Danaher Corporation*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. PerkinElmer, Inc.
11.3. Waters Corporation
11.4. Bruker Corporation
11.5. Thermo Fisher Scientific Inc.
11.6. Agilent Technologies, Inc.
11.7. Shimadzu Corporation
11.8. JEOL Ltd.
11.9. Newomics, Inc.
11.10. LECO Corporation

LIST NOT EXHAUSTIVE